Sio Gene Therapies Inc Up 1.13% To $0.36 After Earnings Beat

Sio Gene Therapies Inc (SIOX) said after close Tuesday that it lost $0.18 per share in quarter four 2022. The company reported $0.00 in revenue

In the same quarter a year ago, the company lost $0.05 per share on revenue of $0.00.

The stock is up 1.13% to $0.36 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

Wall Street Analysts had an average rating of Buy on the stock prior to the report.

InvestorsObserver gives the stock a Neutral Sentiment score at the moment based on recent trading.

Sio Gene Therapies Inc has performed poorly during the past few months, garnering a low Long-Term Technical Rank by InvestorsObserver of 11, putting Sio Gene Therapies Inc in the bottom 25% of stocks. The firm was recently trading at a 52-week low of $0.23 on May 12, 2022 and set a 52-week high on June 28, 2021 at $2.95.

Sio Gene Therapies Inc is a clinical-stage company that is focused on gene therapy for neurodegenerative diseases. The company is developing its pipeline for the treatment of debilitating diseases, including Parkinson's disease, GM1 gangliosidosis, and GM2 gangliosidosis.